BC Extra | Dec 7, 2019
Company News

Dec. 6 Company Quick Takes: Alexion rebuffs activist’s push for sale; plus UCB, Genmab, Enzyvant, Biohaven

Under activist pressure, Alexion decides against proactive sale process  Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) rose 6% Friday, boosting the company’s market cap by $1.4 billion, after the company said in a statement that its...
BC Extra | Sep 4, 2019
Company News

Sept. 4 Company Quick Takes: Boehringer licenses Lupin MEK inhibitor; plus BMS-BioMotiv, KemPharm-GPC, Lilly, Nektar and Intellipharmaceutics

BI licenses Lupin's MEK inhibitor   Boehringer Ingelheim (Ingelheim, Germany) licensed development and commercialization rights to MEK inhibitor LNP3794 from Lupin Ltd. (NSE:LUPIN; BSE:500257), which the pharma plans to test in combination with its KRAS...
BC Extra | Aug 26, 2019
Company News

Aug. 26 Company Quick Takes: J&J ordered to pay $572M in opioid trial; plus Taltz, CVRx and Crozet

J&J to appeal ruling in Oklahoma suit  Oklahoma Judge Thad Balkman ruled that J&J's "misleading marketing and promotion of opioids" compromised the health and safety of thousands of Oklahomans and fined the pharma $572 million....
BC Extra | Aug 13, 2019
Clinical News

Taltz tops Tremfya in psoriasis but data may not change prescribing habits

Eli Lilly said Taltz was superior to J&J's Tremfya in treating psoriasis at 12 weeks in the Phase IV IXORA-R trial, but the data may not move the needle on physicians’ prescribing habits. The data...
BC Extra | Jul 19, 2019
Company News

July 19 Company Quick Takes: First biosimilars of Avastin, Herceptin launched; plus Gilenya, Celltrion-Nan Fung and Celgene

Amgen, Allergan launch pair of biosimilars  Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) launched Mvasi bevacizumab-awwb and Kanjinti trastuzumab-anns in the U.S.; they are the first biosimilars of Avastin bevacizumab and Herceptin trastuzumab available in...
BC Extra | Jun 14, 2019
Clinical News

June 14 Clinical Quick Takes: Chi-Med, BeiGene, UCB, Global Blood and more

Chi-Med’s surufatinib meets in Phase III for extra-pancreatic neuroendocrine tumors  Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said it is planning a pre-NDA meeting with China’s National Medical Products Administration (NMPA) after surufatinib (formerly sulfatinib) met...
BC Extra | May 2, 2019
Company News

CStone adds trispecific antibody to pipeline with Numab deal

CStone will provide early stage R&D funding in exchange for exclusive, Asian rights to develop and commercialize preclinical trispecific antibody ND021 from Numab. The immunotherapy, which targets PD-L1, 4-1BB and human serum albumin, would be...
BC Week In Review | Apr 26, 2019
Clinical News

Lilly planning submissions for Taltz in non-radiographic axial spondyloarthritis

Lilly said it plans to submit regulatory applications this year for Taltz ixekizumab to treat non-radiographic axial spondyloarthritis after the drug met the primary and all major secondary endpoints in the Phase III COAST-X trial....
BC Week In Review | Apr 5, 2019
Company News

China’s NMPA approves Novartis’ Cosentyx for psoriasis

Novartis said China's National Medical Products Administration approved Cosentyx secukinumab to treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Cosentyx was included on China’s first batch of urgently needed...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
Items per page:
1 - 10 of 175